CV Therapeutics (acquired by Gilead Sciences)

I joined CVTX in January 2008 to co-lead our Investor Relations function. I crafted the company’s news releases, scripted quarterly earnings and strategic transaction conference calls, maintained the company’s investor presentation, planned our annual meeting, reviewed and updated our securities filings, and spoke daily with our buy and sell-side analysts trading and covering our company’s stock. During my tenure, CVTX cleared two regulatory milestones in the US and one in the EU. We generated over $250M of non-dilutive cash and following a bidding war, ultimately sold the company for a nearly 3x premium to the market cap of the company when I joined 16 months prior.

Some transactions I covered:

• FDA approval of Ranexa (first-line indication)

• EMA approval of Ranexa

• FDA approval of Lexiscan

• $185M Royalty financing with TPG-Axon Capital

• $385M European licensing deal for Ranexa to Menarini Group

• $1.4B acquisition of CVTX by Gilead Sciences

Deloitte Recap (part of Deloitte Investments)

I joined Recap as a Senior Consultant in December 2009 following the sale of CV Therapeutics to Gilead. Recap developed a reputation for housing the world’s most robust set of public and confidential information about licensing, joint-venture, royalty, and M&A activities between academic, biotech, pharmaceutical, and medical device companies.

We used this proprietary knowledge base - much of which was obtained through Freedom of Information Act requests to the SEC - to become trusted advisors to business development executives within leading biopharma companies.

Some of my responsibilities included:

• Creating new deal records for newly announced transactions capturing metrics including upfront payments, royalties, milestones, co-promotion rights, and governance structures

• Preparing comparable analysis to support our efforts as an Expert Witness in landmark IP litigation (ie: RNAi)

• Speaking at conferences and training courses (ie: QB3)

• Serving on Deloitte’s Regional Advisory board